Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.39 |
| ▸ | ADA | P00813 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6383362 | 1.00 | ADORA2A (0.39) | ADORA2AADAGSK3BADORA3ADORA1 | |
| SCHEMBL6833685 | 0.82 | ADORA2A (0.46) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL6379623 | 0.81 | ADORA2A (0.46) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL6379675 | 0.77 | ADORA2A (0.58) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL6382950 | 0.77 | ADORA2A (0.58) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL18484829 | 0.76 | ADORA2A (0.48) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL19322740 | 0.76 | ADORA2A (0.48) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL5008834 | 0.73 | ADORA2A (0.46) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL12031305 | 0.73 | ADORA2A (0.62) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL14470815 | 0.73 | ADORA2A (0.62) | ADORA2AADAADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | ADORA2A 174/4885ADA 13/4885GSK3B 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.